Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda    save search
Jaypirca® (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor
Published: 2023-12-01 (Crawled : 23:00) - prnewswire.com
LLY 2 d | $584.04 -1.18% 0.34% 3.6M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
jaypirca fda approved treatment leukemia
No embecta-made syringes impacted by FDA safety communication
Published: 2023-12-01 (Crawled : 17:00) - globenewswire.com
EMBC F | $18.42 1.26% 1.2% 750K twitter stocktwits trandingview |
n/a
 | | O: -1.94% H: 0.0% C: 0.0%
fda communication
Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)
Published: 2023-12-01 (Crawled : 15:30) - biospace.com/
CING | $6.27 1.13% -5.1% 79K twitter stocktwits trandingview |
| | O: 1735.48% H: 0.0% C: 0.0%
fda
Scilex Holding Company announces successful FDA audit of enhanced ZTlido® manufacturing facility in Japan
Published: 2023-11-30 (Crawled : 08:00) - globenewswire.com
SCLX | $1.35 8.0% 2.96% 870K twitter stocktwits trandingview |
| | O: -2.86% H: 0.0% C: 0.0%
ztlido fda company japan
Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis
Published: 2023-11-30 (Crawled : 00:00) - biospace.com/
BIOR | $1.35 8.87% -2.96% 12M twitter stocktwits trandingview |
Health Care and Social Assistan...
 | | O: 1.65% H: 0.0% C: 0.0%
bt-600 fda treatment clearance application therapeutics
FDA Safety Communication Does Not Impact BD Syringes
Published: 2023-11-30 (Crawled : 00:00) - prnewswire.com
BDX S | $238.25 0.88% 0.37% 1.5M twitter stocktwits trandingview |
Health Technology
 | | O: 0.01% H: 0.0% C: 0.0%
fda communication impact
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2023-11-30 (Crawled : 22:00) - prnewswire.com
PFE | $28.91 -5.12% 0.0% 100M twitter stocktwits trandingview |
Health Technology
 | | O: -4.15% H: 0.0% C: 0.0%
padcev fda license review bladder cancer treatment application grants
Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH
Published: 2023-11-30 (Crawled : 15:30) - biospace.com/
ORTX | $16.21 -0.56% 79K twitter stocktwits trandingview |
Health Technology
 | | O: 0.12% H: 0.0% C: 0.0%
otl-203 fda designation mps-ih therapeutics
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease
Published: 2023-11-30 (Crawled : 15:30) - biospace.com/
SNGX | $0.73 75.73% -5.49% 7M twitter stocktwits trandingview |
Health Technology
 | | O: 32.76% H: 0.0% C: 0.0%
fda disease treatment clearance trial
Edgewise Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
EWTX | $6.19 1.81% 2.01% 900K twitter stocktwits trandingview |
Manufacturing
 | | O: 8.68% H: 0.0% C: 0.0%
fda rare drug disease program
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
LTRN S | $3.74 -5.32% -4.77% 61K twitter stocktwits trandingview |
Health Technology
 | | O: 2.81% H: 0.0% C: -1.74%
lp-284 fda pharma drug candidate designation lymphomas grants
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry DiseasePatient enrollment expected to begin in first half of 2024
Published: 2023-11-29 (Crawled : 14:30) - biospace.com/
QURE | $7.14 5.31% 4.84% 740K twitter stocktwits trandingview |
Health Technology
 | | O: 3.25% H: 4.58% C: -2.58%
amt-191 fda drug expected clearance application therapy
Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development
Published: 2023-11-29 (Crawled : 13:00) - globenewswire.com
KTTA | $0.319 -2.15% -4.12% 32K twitter stocktwits trandingview |
| | O: 2.57% H: 0.0% C: 0.0%
pas-004 fda meeting therapeutics
FDA Accepts Arcutis’ Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6
Published: 2023-11-29 (Crawled : 13:00) - globenewswire.com
ARQT M | $1.99 8.15% 0.0% 2.9M twitter stocktwits trandingview |
Health Technology
 | | O: 3.43% H: 0.0% C: 0.0%
fda drug children dermatitis treatment application
Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea
Published: 2023-11-29 (Crawled : 12:30) - globenewswire.com
VVOS | $19.9 -18.78% -8.84% 1.9M twitter stocktwits trandingview |
Health Technology
 | | O: 172.67% H: 0.0% C: 0.0%
fda device treatment clearance therapeutics
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
Published: 2023-11-29 (Crawled : 12:00) - globenewswire.com
QURE | $7.14 5.31% 4.84% 740K twitter stocktwits trandingview |
Health Technology
 | | O: 3.25% H: 4.58% C: -2.58%
amt-191 fda drug disease clearance application therapy
FDA Launches Probe of Malignancies Linked to CAR-T Therapies
Published: 2023-11-28 (Crawled : 00:00) - biospace.com/
JNJ | $158.38 2.41% 0.0% 10M twitter stocktwits trandingview |
Health Technology
 | | O: 0.09% H: 0.0% C: 0.0%
fda car-t
FDA Roundup: November 28, 2023
Published: 2023-11-28 (Crawled : 22:00) - prnewswire.com
SWTX | $31.9 4.97% 4.64% 1.5M twitter stocktwits trandingview |
Health Technology
 | | O: 9.86% H: 11.94% C: 6.05%
fda
GE HealthCare Expands On-Device Triage Capabilities of Critical Care Suite with FDA Clearance of Algorithm for Pneumothorax Detection, Notification, Triage and Diagnosis
Published: 2023-11-28 (Crawled : 20:00) - biospace.com/
GEHC | $69.41 1.39% -0.16% 1.9M twitter stocktwits trandingview |
n/a
 | | O: -0.62% H: 0.12% C: -3.64%
fda care clearance
FDA Decisions: First Treatment for Desmoid Tumors and a Dry Eye Rejection for Aldeyra
Published: 2023-11-28 (Crawled : 15:00) - biospace.com/
SNYNF | $94.0 1.34% 1.34% 860 twitter stocktwits trandingview |
Health Technology
 | | O: -1.89% H: 0.02% C: 0.02%
PRGO P | $30.9 1.44% 0.0% 1.3M twitter stocktwits trandingview |
Health Technology
 | | O: 0.78% H: 0.81% C: -1.71%
JNJ | $158.38 2.41% 0.0% 10M twitter stocktwits trandingview |
Health Technology
 | | O: 0.09% H: 0.0% C: 0.0%
ABT | $104.88 0.57% -0.01% 4.7M twitter stocktwits trandingview |
Health Technology
 | | O: -0.24% H: 0.03% C: -0.39%
SNY | $46.72 -0.06% -0.06% 1.1M twitter stocktwits trandingview |
Health Technology
 | | O: -1.41% H: 0.87% C: 0.0%
fda tumors treatment eye
Gainers vs Losers
77% 23%

Top 10 Gainers
ID 4 | $0.077 -9.41% 25.97% 420K twitter stocktwits trandingview |
Finance
BKKT 4 | $1.88 25.33% 14.89% 4.8M twitter stocktwits trandingview |

MGLD | $1.03 7.77% 14K twitter stocktwits trandingview |
Manufacturing
CZOO | $0.4316 -6.52% 6.7% 65K twitter stocktwits trandingview |

SATX | $0.4226 -1.72% 6.48% 29K twitter stocktwits trandingview |
n/a
CCJ | $45.4 -1.13% 4.6% 3.9M twitter stocktwits trandingview |
Non-Energy Minerals
AUMN | $0.562 0.34% 4.5% 360K twitter stocktwits trandingview |
Non-Energy Minerals
JBL | $116.91 1.38% 4.3% 2M twitter stocktwits trandingview |
Electronic Technology
SAIC 4 | $119.92 2.14% 4.24% 460K twitter stocktwits trandingview |
Technology Services
CULP 4 | $5.06 -0.59% 3.95% 29K twitter stocktwits trandingview |
Process Industries
Your saved searches
Save your searches and get alerts when important news are released.